FORT MILLS, SC / ACCESSWIRE / July 15, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that its previously announced 1-for-10 reverse stock split of its common stock became effective at 12:01 A.M. Eastern Time, on July 15, 2024. The Company's common stock will continue to be traded on the NYSE American under the symbol "VTAK" and will begin trading on a split-adjusted basis when the market opens on July 15, 2024. The new CUSIP number for the Company's common stock following the reverse stock split will be 74933X 609.
Pursuant to the reverse stock split, every 10 shares of the Company's issued common stock will be converted automatically into one issued share of common stock without any change in the par value per share. Stockholders holding shares through book entry on the Company's records will have their shares automatically adjusted to reflect the 1-for-10 reverse stock split. It is not necessary for stockholders holding shares of the Company's common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.
The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. No fractional shares of common stock will be issued in connection with the reverse split. Stockholders of record who otherwise would be entitled to receive fractional shares, will be entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses).
The reverse stock split will reduce the number of issued shares of the Company's common stock from 9,012,518 shares to approximately 901,251 shares. Proportional adjustments will be made to the number of shares of the Company's common stock issuable upon exercise or conversion of the Company's equity awards and warrants and other convertible securities, as well as the applicable exercise price, to the extent applicable. Stockholders whose shares are held in brokerage accounts should direct any questions concerning the reverse stock split to their broker. All stockholders of record may direct questions to the Company's transfer agent, Equiniti Trust Company, via email at and select GET HELP or by telephone at (800) 937-5449 or (718) 921-8124.
Additional information about the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on May 16 2024, which is available free of charge at the SEC's website, www.sec.gov, and on the Company's website at .
"While the reverse stock split is primarily designed to help ensure our continued technical compliance with the NYSE American minimum stock price requirement and allow us to lower our Delaware franchise taxes, we also hope to broaden the base of potential investors in Catheter Precision as we strive for greater efficiencies, increased cash flow and profitable growth. The split also has no direct impact on our market capitalization," said David Jenkins, Chief Executive Officer.
Forward-Looking Statements
Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," "would," "forward," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding the potential impact of the reverse stock split and the Company's plans. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to the risk that members of the EP community and other doctors and hospitals will fail to recognize VIVO's value or for other reasons will prefer other methodologies and/or products, including the products of our current competitors as well as possible new and emerging competing products of which we are not yet aware; the risk that customers and new distributors, including Hamad Medical Corporation, which has not entered into a long term purchasing contract with us, may not make additional purchases in the future, and that our business relationship with them and/or other distributors and/or persons in Qatar and elsewhere in the Middle East could be disrupted by the armed conflict in Israel and the Gaza strip and/or changes in U.S. international relations and/or related geopolitical changes; and other risks and uncertainties attendant to our business included under the caption "Risk Factors" in the Company's Form 10-K and other SEC filings available at www.sec.gov. These additional risks and uncertainties include, but aren't limited to, risks that our cash needs will continue to exceed our liquidity, we will not be able to reach profitability unless we are able to achieve our product expansion and growth goals, our research and development and commercialization efforts may depend on entering into agreements with corporate collaborators, we have entered into joint marketing agreements with respect to our products, and may enter into additional joint marketing agreements, that will reduce our revenues from product sales, royalty agreements with respect to our LockeT device will reduce any future profits from this product, if we experience significant disruptions in our information technology systems, our business may be adversely affected, litigation and other legal proceedings may adversely affect our business, if we make acquisitions or divestitures, we could encounter difficulties that harm our business, failure to attract and retain sufficient qualified personnel could also impede our growth, failure to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock, we have determined that our internal controls and disclosure controls were not effective as of December 31, 2023 and March 31, 2024, and as a result, without effective remediation of the material weaknesses that we have identified, we may not be able to accurately report our financial results or prevent fraud, our revenues may depend on our customers' receipt of adequate reimbursement from private insurers and government sponsored healthcare programs, we may be unable to compete successfully with companies in our highly competitive industry, many of whom have substantially greater resources than we do, our future operating results depend upon our ability to obtain components and finished product in sufficient quantities on commercially reasonable terms or according to schedules, prices, quality and volumes that are acceptable to us, and suppliers may fail to deliver components or finished product, or we may be unable to manage these components or product procurement effectively or obtain these components or products on such terms, if hospitals, physicians and patients do not accept our current and future products or if the market for indications for which any product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any, our medical device operations are subject to pervasive and continuing FDA regulatory requirements, our products may be subject to potential product liability risks as well as additional recalls, revocations or suspensions after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation, and adversely affect our business, changes in trade policies among the U.S. and other countries, in particular the imposition of new or higher tariffs, could place pressure on our average selling prices as our customers seek to offset the impact of increased tariffs on their own products, increased tariffs or the imposition of other barriers to international trade could have a material adverse effect on our revenues and operating results. The risks and uncertainties described above may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, or other pandemics, disruptions to our ability to conduct business overseas, including to our supply chain, from the Ukraine war, the Israeli-Hamas armed conflict and other ongoing hostilities and instabilities in the Middle East and elsewhere, and ongoing volatility in the stock markets and the U.S. economy in general. In addition, market conditions that are outside our control could significantly influence the impact of the reverse stock split on our stock price and how our stock is viewed by potential investors.
CONTACTS:
At the Company
David Jenkins
973-691-2000
IR@catheterprecision.com
SOURCE: Catheter Precision, Inc
2024年7月15日、米国の革新的な医療機器企業Catheter Precision, Inc.(NYSE American:VTAK)は、これまでに発表されたCommon Stockの1株に対して10株の株式分割が、2024年7月15日の午前12時01分(米国東部時間)に効果を発揮することを発表しました。同社のCommon Stockは引き続きNASDAQ Americanのシンボル「VTAK」で取引され、2024年7月15日の市場開始時に株式分割に対応した取引が開始されます。株式分割後、同社のCommon Stockの新しいCUSIP番号は74933X 609になります。
株式分割により、同社の発行するCommon Stockの10株につき、株価の変更はないまま自動的に1株のCommon Stockに転換されます。同社記録の書籍エントリーを通じて株式を保持している株主は、株式が自動的に調整されて、1株に10株の株式分割が反映されます。株式名義証の形式で同社へ株主が保持している場合、逆株式分割に関連して、既存の株式証明書を新しい株式証明書と交換する必要はありませんが、株主が望む場合は交換することができます。
逆株式分割は株主すべてに均等に影響し、株主の持分比率を変更することはありません。ただし、逆株式分割により株主が単位未満株を所有することになる場合は、単位未満株が発行されることはありません。新しい単位未満株から生じる含み株式の集約と売却によって得られた純収益の割り当てを受け取る権利が株主に与えられます(通常の仲介手数料、手数料、その他の費用を差し引いたものです)。
逆株式分割により、同社のCommon Stockの発行済み株式数は9,012,518株から約901,251株に減少します。同社のCommon Stock発行可能数や、同社の株式報酬や株式引換権などの可換性証券についても比例的に調整されます。株式会社の株式が備え付けの記録を通じて保有されている株主は、逆株式分割に関する質問は、ブローカーに指示する必要があります。株主すべてが、同社の移転代理店であるEquiniti Trust Companyに質問をすることができます。詳細については、eメール または(800) 937-5449 または(718) 921-8124で、カスタマーサービスを選択して、GEt HELPを選択して、同社に問い合わせることができます。
逆株式分割に関する詳細情報は、同社の2022年5月16日に証券取引委員会("SEC")に提出された決定権のあるプロキシ声明書で入手できます。同書は無料でSECのウェブサイトwww.sec.govと同社のウェブサイトで入手できます。
"逆株式分割は、主にNASDAQ American株価要件の最低水準を満たすためのテクニカルなコンプライアンスを確保すること、デラウェア・フランチャイズ税を引き下げることを目的としていますが、より効率的で、キャッシュフローが増加し、利益になる成長を目指しているカテーテルプレシジョンの潜在的な投資家のベースを広げることを期待しています。また、スプリットは、当社の時価総額に直接的な影響はありません。"と、David Jenkins最高経営責任者は述べています。
出典:Nutex Health, Inc。
本プレスリリースは、Private Securities Litigation Reform Act of 1995に基づく「前向きな声明」を含む場合があり、これらの前向きな声明は、"信じる"、"先を見据える"、"可能性がある"、"しがち"、"できる"、"続く"、"依存する"、"期待する"、"拡大する"、"予測する"、"計画する"、"頼る"、"すべき"、"意志"、"可能性がある"、などの言葉で特定されることがあります。これらの前向きな声明には、逆株式分割の潜在的な影響や当社の計画のような事項が含まれます。重要な事項が実現されない可能性があります。実際には、不確実性、リスク、状況の変化などにより、これらの前向きな声明が示す結果や成果は、異なる場合があります。これらの前向きな声明に伴うリスクと不確実性には、米国証券取引委員会が無料で提供する、会社の10-KフォームなどのSECファイリングに記載されている"リスクファクター"キャプションに記載されたものがあります。
連絡先:
会社で
デビッド・ジェンキンス
973-691-2000
IR@catheterprecision.com
ソース:Catheter Precision, Inc